What is Aquestive Therapeutics, Inc.'s prepaid expenses?

Aquestive Therapeutics, Inc. (AQST) reported prepaid expenses of $586K in Q4 2025.

What is the long-term trend for Aquestive Therapeutics, Inc.'s prepaid expenses?

Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s prepaid expenses has grown at a 14.2% compound annual growth rate (CAGR), from $449K to $586K.

Aquestive Therapeutics, Inc. AQST Prepaid expenses

Other financials

Income statement

See full

Revenue$14.4M+65.7%

Gross profit$11.0M+117%

Operating income-$4.2M+78.3%

Net income-$8.1M+64.9%

EPS (diluted)-$0.07+70.8%

Balance sheet

See full

Cash & equivalents$110.7M+61.3%

Total debt$64.4M+7.4%

Total equity-$34.1M+44.1%

Total assets$141.1M+38.0%

Cash flow

See full

Operating cash flow-$14.8M+36.7%

CapEx$52.0K-61.5%

Free cash flow-$14.9M+36.9%

Valuation

See full

Market cap$560.13M+73.5%

Enterprise value$513.76M+63.6%

P/S11.1×+5.2×

Profitability

See full

Gross margin63.5%-4.9pp

Operating margin-111.2%+96.3pp

Net margin-137.1%+80.7pp

FCF margin-88.2%-2.2pp

Returns & leverage

See full

Return on equity145.1%—

Debt / equity-1.9×—

Current ratio4.1×-0.8×

Where this comes from

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxLiabilitiesPrepaidExpenses.

The official record: Aquestive Therapeutics, Inc.’s 10-K, filed March 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aquestive Therapeutics, Inc.'s prepaid expenses.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aquestive Therapeutics, Inc.'s prepaid expenses?: Aquestive Therapeutics, Inc. (AQST) reported prepaid expenses of $586K in Q4 2025.
What is the long-term trend for Aquestive Therapeutics, Inc.'s prepaid expenses?: Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s prepaid expenses has grown at a 14.2% compound annual growth rate (CAGR), from $449K to $586K.